<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">Based on these definitions, the questions this review will address are as follows: 
 <list list-type="order">
  <list-item>
   <p id="Par25">What levels of evidence support signals of adverse drug reactions, and SDRs, communicated by drug regulatory authorities or other pharmacovigilance stakeholders?</p>
  </list-item>
  <list-item>
   <p id="Par26">What are the similarities and differences between the levels of evidence supporting signals from different stakeholders?</p>
  </list-item>
  <list-item>
   <p id="Par27">Have the levels of evidence changed over time?</p>
  </list-item>
  <list-item>
   <p id="Par28">What is the interval between a signal and the first report of the corresponding suspected adverse drug reaction?</p>
  </list-item>
  <list-item>
   <p id="Par29">Has this interval shortened or increased over the years?</p>
  </list-item>
  <list-item>
   <p id="Par30">In the case of signals supported by reports of adverse drug reactions, what features of the reports have led authors to signal suspected drug-related harms?</p>
  </list-item>
 </list>
</p>
